Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection

Fu, Qin; Meng, Fandong; Shen, Xiao-Dong; Guo, Ren-Xuan

doi:10.3748/wjg.v8.i6.1019

Cited by 19 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, IL-2 and IL-12 activate natural killer (NK) cells, and CD4+ and CD8+ T cells (cytotoxic T lymphocytes) resulting in tumor destruction. Thus, IL-2 and IL-12 have been used in the intraperitoneal immunotherapy of patients with various cancers including gastric cancer [15][16][17]. IL-2 gene expression was especially suppressed in the untreated peritoneal cavity of the SGC patients, and as emphasized by Fu et al [17], IPC combined with IL-2 immunotherapy might be therapeutically beneficial for SGC patients.…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic-Assisted Intraperitoneal Chemotherapy for Patients with Scirrhous Gastric Cancer

Ikeguchi

Matsumoto²,

Yoshioka³

et al. 2005

Chemotherapy

View full text Add to dashboard Cite

Background: The prognosis for patients with scirrhous gastric cancer (SGC) is extremely poor. To improve the patients’ prognosis, laparoscopic-assisted intraperitoneal chemotherapy (IPC) was introduced for SGC. In this study, we analyzed whether IPC reduced the number of cancer cells in the peritoneal cavity of patients or changed the gene expression levels of cytokines in the peritoneal cavity. We also investigated whether IPC improved the prognosis of patients with SGC. Methods: Total RNA was extracted from 50 ml of peritoneal wash from 11 SGC patients before and after cisplatin-based IPC. The gene expression levels of survivin, c-myc, transforming growth factor-β (TGF-β), interleukin-2 (IL-2), IL-6, and IL-12 were analyzed using real-time reverse transcription-polymerase chain reaction (RT-PCR) assays. Also, carcinoembrionic antigen (CEA) messenger RNA (mRNA) was used to identify the number of gastric cancer cells in peritoneal washes by the real-time RT-PCR method. The gene expression levels of cytokines and the number of cancer cells in the peritoneal cavity were compared before and after cisplatin-based IPC treatment. Results: Before IPC, the gene expression of IL-2 from peritoneal washes of patients was significantly suppressed compared to the controls (p = 0.029); however, other gene expression levels did not differ. In 7 cases, more than 90% of the cancer cells were removed from the peritoneal cavity after cisplatin-based IPC. These 7 cases were named the IPC effective group, and the remaining 4 cases were named the IPC ineffective group. In the IPC effective group, elevated IL-2 and IL-6 genes were detected in 5 (71%) and in 6 (86%) after IPC. The correlation between IPC effectiveness and elevated gene expression after IPC (IL-2: p = 0.137, and IL-6: p = 0.044) was observed. However, the 50% survival period of the IPC effective group (9 months) was not different from that of that of the IPC ineffective group (6 months, p = 0.267). Conclusion: IPC effectiveness may correlate with elevation of gene expression of inflammatory cytokines, such as IL-2 and IL-6 in the peritoneal cavity after IPC. However, the prognostic benefits of IPC for SGC patients remain unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

Laparoscopic-Assisted Intraperitoneal Chemotherapy for Patients with Scirrhous Gastric Cancer

Ikeguchi

Matsumoto²,

Yoshioka³

et al. 2005

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…IL-2 was also used to improve the anti-tumor activity of other forms of immunotherapy [143][144][145][146][147][148][149][150] chemotherapy [151][152][153][154][155][156] and surgery [157][158][159][160][161][162][163].…”

Section: Discussionmentioning

confidence: 99%

Gastric Cancer Immunotherapy: An Overview

Romano¹,

Uggeri²,

Nespoli³

et al. 2013

JCT

View full text Add to dashboard Cite

Gastric adenocarcinoma is the third most common cancer and the second most common cause of death due to cancer worldwide. Surgery is still the major prognostic factor for gastric cancer. Patients who could not be resected have a poor prognosis with survival ranging from 3 to 11 months. There is evidence that surgical operations can cause a variety of immunological disturbances in man both in vivo and in vitro. The postoperative changes in the systemic immune response are proportional to the degree of surgical trauma leading to a generalized state of immunosuppression, which is implicated in the development of septic complications and provided a "fertile soil" for tumor cell metastasis. Immunotherapy may be a potentially promising alternative strategy for gastric cancer. In early clinical trials, systemic immunotherapy included both active vaccination directed against defined tumor-associated antigens expressed in gastric carcinoma cells and passive administration of IL-2 with some evidence of regression of metastatic gastric cancer. Other studies have applied immunotherapy in the adjuvant setting with equally promising results. For example, OK-432, a streptococcal preparation, demonstrated marginal improvement in survival for patients with stage III gastric cancer and a meta-analysis of centrally randomized controlled clinical trials indicated a significant survival benefit with combination OK-432 and chemotherapy compared to chemotherapy alone (p < 0.05). Additional data suggesting a biological and clinical benefit of subcutaneous, preoperative administration of low-dose IL-2 in colon cancer encouraged us to evaluate low-dose IL-2 therapy in the neoadjuvant setting for patients with gastric adenocarcinoma who undergo surgery and to evaluate its effects on systemic and tumor infiltrating lymphocyte numbers. We also sought to determine if neoadjuvant low-dose IL-2 could influence the clinical outcome for patients undergoing gastric resection for cancer. We report the biological, histological and clinical results with the full accrual of patients and a median follow-up of 51 months.

show abstract

“…chemotherapy combined with or without hyperthermia, immunotherapy, and cytoreductive surgery [19][20][21]. However, the efficacy of the therapy remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Preoperative intraperitoneal chemotherapy for patients with serosa‐infiltrating gastric cancer

Yano

Yasuda

Fujiwara

et al. 2004

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection

Abstract: The combination of intraperitoneal IL-2 immunotherapy and thermochemotherapy could promote Th1 immune paradigm and enforce anti-tumor activity of bodies, which plays a positive role in preventing gastric and colorectal cancer from intraperitoneal recurrence and development.

Cited by 19 publications

References 29 publications

Laparoscopic-Assisted Intraperitoneal Chemotherapy for Patients with Scirrhous Gastric Cancer

Laparoscopic-Assisted Intraperitoneal Chemotherapy for Patients with Scirrhous Gastric Cancer

Gastric Cancer Immunotherapy: An Overview

Preoperative intraperitoneal chemotherapy for patients with serosa‐infiltrating gastric cancer

Contact Info

Product

Resources

About